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Abstract
Background
Posterior Cortical Atrophy (PCA) is a neurodegenerative disease characterized by a pro-
gressive decline in selective cognitive functions anatomically referred to occipital, parietal
and temporal brain regions, whose diagnosis is rather challenging for clinicians. The aim of
this study was to assess, using quantitative Magnetic Resonance Imaging techniques, the
pattern of regional grey matter loss and metabolism in individuals with PCA to improve
pathophysiological comprehension and diagnostic confidence.
Methods
We enrolled 5 patients with PCA and 5 matched controls who all underwent magnetic reso-
nance imaging (MRI) and spectroscopy (MRS). Patients also underwent neuropsychologi-
cal and cerebrospinal fluid (CSF) assessments. MRI data were used for unbiased
assessment of regional grey matter loss in PCA patients compared to controls. MRS data
were obtained from a set of brain regions, including the occipital lobe and the centrum semi-
ovale bilaterally, and the posterior and anterior cingulate.
Results
VBM analysis documented the presence of focal brain atrophy in the occipital lobes and in
the posterior parietal and temporal lobes bilaterally but more pronounced on the right hemi-
sphere. MRS revealed, in the occipital lobes and in the posterior cingulate cortex of PCA
patients, reduced levels of N-Acetyl Aspartate (NAA, a marker of neurodegeneration) and
increased levels of Myo-Inositol (Ins, a glial marker), with no hemispheric lateralization.
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Conclusion
The bilateral but asymmetric pattern of regional grey matter loss is consistent with patients’
clinical and neuropsychological features and with previous literature. The MRS findings
reveal different stages of neurodegeneration (neuronal loss; gliosis), which coexist and
likely precede the occurrence of brain tissue loss, and might represent early biomarkers. In
conclusion, this study indicates the potential usefulness of a multi-parametric MRI approach
for an early diagnosis and staging of patients with PCA.
Introduction
Posterior Cortical Atrophy (PCA) is a neurodegenerative disease which is clinically character-
ized by a progressive and selective decline in visual-processing skills and in other functions
localized in the occipital, parietal and temporal brain regions. In contrast, memory and lan-
guage abilities are relatively preserved, at least at early clinical stages of the disease [1]. PCA is
currently considered as a clinical variant of Alzheimer’s disease (AD), due to pathological evi-
dence of neurofibrillary tangles and neuritic plaques deposition as the most frequent findings
in the affected regions of the brain [2,3]. Nevertheless, in clinical practice, the diagnosis of PCA
is rather challenging due to the unusual clinical onset for AD, the lack of validated diagnostic
criteria and awareness among clinicians [4].
Earlier studies based on visual assessment of magnetic resonance (MR) images have consis-
tently reported a bilateral pattern of posterior brain atrophy (i.e., affecting the occipital, parietal
and temporal lobes) in cases of PCA [5,6,7,8,9,10,11,12]. More recently, voxel-based-mor-
phometry (VBM), which is an automated and unbiased technique for assessing regional brain
volumetrics, has shown a predominant distribution of posterior brain atrophy to the right
hemisphere of patients with PCA [13,14]. The intrinsic limitation of volumetric studies is the
inability in providing any information about the pathophysiological processes preceding the
brain tissue loss. In this perspective, proton MR spectroscopy (1H-MRS) is a noninvasive tech-
nique with the ability to provide metabolic information from the brain tissue in vivo. Several
metabolites of pathophysiological interest can be quantified using 1H-MRS, as demonstrated
by its successful application to various forms of degenerative dementia [15,16]. Reduced levels
of N-Acetyl-Aspartate (NAA) (a marker of neuronal integrity) and increased levels of myo-
Inositol (Ins) (a marker of glial activity) have been identified with specific patterns of anatomi-
cal distribution in the brain of patients with typical AD and with frontotemporal dementia
[15,16]. So far, to the best of our knowledge, 1H-MRS was used to investigate PCA brains in
one previous study only [13]. In that study, Whitwell et al. (2007) focused their investigation
on the posterior cingulate gyrus and the precuneus of patients with PCA as compared to
patients with typical AD, without reporting any significant metabolic difference between
groups [13].
The aim of this study was to assess the regional pattern of grey matter loss and brain metab-
olites profile in individuals with PCA and to correlate the macrostructural data obtained from
VBM to microstructural data obtained from 1HMRS.
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Materials and Methods
Subjects
Five patients affected by PCA as diagnosed by clinical criteria, were enrolled in the study. Prin-
cipal patients’ characteristics are summarized in Table 1. The clinical workup included medical
history, physical and neurological examination and screening laboratory tests. Additionally, as
detailed below and summarized in Table 2, all patients underwent an extensive neuropsycho-
logical battery exploring global cognition and all major cognitive domains. According to the
clinical characteristics identified by Crutch et al. [4], patients had to fulfill the following criteria:
1) an insidious clinical onset and a gradual progression of symptoms; 2) a cognitive profile
dominated by visuoperceptual and visuospatial impairments in the absence of any remarkable
deficit of vision itself; 3) a relative preservation of memory and insight; 4) the presence of a
complex visual disorder (i.e., elements of Balint’s syndrome or Gerstmann’s syndrome, visual
field defects, visual agnosia, environmental disorientation); 5) exclusion of any other alterna-
tive diagnosis accounting for patients’ clinical features such as stroke or tumor.
All patients underwent lumbar puncture for CSF quantification by ELISA (Fujurebio, Gent,
Belgium) of Beta-Amyloid, Tau and Tau phosphorylated at position 181 (Ptau) proteins.
Five healthy subjects (HS), matched for age and gender with PCA patients, were also
enrolled in the study and served as controls. All control subjects underwent a neurological
examination to exclude any remarkable impairment.
Moreover, major systemic, psychiatric, and other neurological illnesses were carefully inves-
tigated and excluded in all recruited subjects.
The current research study was approved by the Ethics Committee of Foundation IRCCS
Ca' Granda Ospedale Maggiore Policlinico, and all procedures followed were in accordance
with the ethical standards of the responsible committee on human experimentation (institu-
tional) and with the Helsinki Declaration of 1975 (and as revised in 1983). All subjects (patients
and controls) gave written informed consent before entering the study.
Neuropsychological assessment
The neuropsychological battery used to test the patients with PCA included: Mini Mental State
Examination (MMSE) [17]; Visual Object and Spatial Perception (VOSP) battery [18], short
story recall test [19], digit span [20], Corsi block tapping task [20], phonological word fluency
[21], naming objects [22] and semantic word fluency [23].
For all employed tests, we used the Italian normative data for score adjustment (age, gender,
and education) and for the definition of cut-off scores of normality (determined as the lower
limit of the 95% tolerance interval for a confidence level of 95%). For each test, normative data
are reported in the corresponding references.
Table 1. Principal characteristics of studied patients.
Age 59 70 72 74 78
Sex M F F M F
MMSE score (cut-off<24.0) 17.5 15.0 24.0 13.8 16.8
CSF Amyloid β (cut-off> 600pg/ml) 253 375 532 532 528
CSF Total Tau (cut-off< 500pg/ml) 312 983 766 1222 855
CSF Phospho-Tau (cut-off< 61pg/ml) 41 87 89 121 83
Abbreviations: MMSE = Mini Mental State Examination; CSF = cerebro-spinal ﬂuid.
There are summarized here the principal features of all studied patients.
doi:10.1371/journal.pone.0140639.t001
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Conventional MRI and volumetric brain acquisitions
All MRI data were acquired at 1.5 T (Siemens Avanto, Erlangen, Germany) equipped with an
head matrix coil. 3D magnetization-prepared rapid gradient echo (MPRAGE) T1-weighted
scan (TR 2300 ms, TE 2.84 ms, in-plane field of view [FOV] 512 x 512 mm2, slice thickness 1
mm, flip angle 12°) was acquired from all recruited subjects. T1-weighted images were visually
inspected for a qualitative assessment of macroscopic atrophy, and to check for the quality of
data before carrying out a quantitative volumetric analysis. Additionally, in all subjects, a
T2-weighted scan (TR 5750 ms, TE 108 ms, field of view 280 x 320, slice thickness 5 mm) was
collected to exclude the presence of any remarkable macroscopic brain abnormality.
Voxel-based morphometry
MRI data were processed using an optimized VBM protocol in Statistical Parametric Mapping
8 (SPM8; Wellcome Department of Imaging Neuroscience; www.fil.ion.ucl.ac.uk/spm/).
Briefly, for each subject, segmentation and normalization produced a GM probability map [24]
in Montreal Neurological Institute (MNI) coordinates. To compensate for compression or
expansion during warping of images to match the template, GMmaps were modulated by mul-
tiplying the intensity of each voxel by the local value derived from the deformation field [25].
All data were then smoothed using a 12-mm full width half maximum (FWHM) Gaussian ker-
nel. Modulated and smoothed GMmaps were analyzed in SPM8, using a sample t-test for the
Table 2. Neuropsychological assessment of PCA patients.
Cut-off Mean (SD)
Global cognition
MMSE [17] >24.0 17.5 (3.9)
Visuo-spatial abilities
VOSP battery [18]
Object perception
Incomplete Letters >16.0 2.5 (1.7)
Silhouettes >15.0 5.2 (3.9)
Object Decision >14.0 9.7 (4.3)
Progressive Silhouettes >15.0 3.2 (4.7)
Space perception
Dot counting >8.0 5.0 (4.1)
Position discrimination >18.0 12.5 (4.6)
Number location >7.0 2.0 (1.0)
Cube analysis >6.0 2.0 (2.0)
Episodic memory
Short story recall test [19] >4.7 3.2 (2.4)
Short term memory
Digit span [20] >3.7 3.7 (0.9)
Corsi block tapping task [20] >3.5 2.3 (2.4)
Executive functions
Phonological word ﬂuency [21] >17.3 26.7 (4.8)
Language
Naming object [22] >43.0 28.5 (13.9)
Semantic word ﬂuency [23] >25.0 19.0 (5.0)
Abbreviations: MMSE = Mini Mental State Examination; VOSP = Visual Object and Spatial Perception
doi:10.1371/journal.pone.0140639.t002
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comparison between patients and controls and a regression model for assessing possible associ-
ations between patients’ regional grey matter volumes and CSF levels of tau (marker of neuro-
degeneration). Total intracranial volume (ICV), age and gender were entered as covariates of
no interest. For every T-contrast, we applied the family wise error (FWE) correction for multi-
ple comparisons, and we accepted as significant p values of less than 0.05 at cluster level.
Single Voxel 1H MRS
In a dedicated session, all subjects underwent 1H-MRS. 1H-MR spectra were acquired without
and with partial water suppression, from the following 20x20x20mm volumes of interest
(VOIs): 1) VOI 1 and 2, aligned along the calcarine fissure and located within the white matter
of each occipital lobe (right and left); 2) VOI 3 and 4, located in the posterior and anterior cin-
gulate cortex; 3) VOI 5 and 6, located within the centrum semiovale of the right and left hemi-
sphere (See Fig 1). Data were obtained under baseline conditions, with the participants lying in
a diminished light, asking them to keep their eyes closed. A point resolved spectroscopy
sequence (PRESS) was employed for spectra collection, setting the following acquisition
parameters: TR 4000 ms, TE 30 ms, 1024 points per spectrum, 32 acquisitions in partial water
suppression spectra and 8 acquisitions in water suppression spectra.
Spectral analysis was performed, and data quantified, using the Linear Combination of
Model spectra (LCModel, http://s-provencher.com/pages/lcmodel.shtml) method and software
[26]. In each VOI, the metabolite groups quantified with a good signal-to-noise ratio (SNR)
were: the N-acetyl aspartate (NAA), Creatine (Cr), Choline (Cho) and myo-Inositol (Ins). As
previously described [13,27], the following metabolite ratios were calculated from each spec-
trum, and used for between-group comparisons: NAA/Cr, Ins/Cr, Cho/Cr. Finally, to reduce
inter-subject variability and minimize the risk of type II errors, for each bilateral VOI (i.e.,
VOIs 1 and 2, and VOIs 5 and 6) metabolite ratios were averaged. Two-tailed unpaired Stu-
dent’s t-tests were used for between group comparisons, with statistical threshold set to p val-
ues<0.012 after Bonferroni’s correction for multiple comparisons.
Results
Subject Characteristics
Principal characteristics of the studied group of PCA patients are summarized in Table 1.
There were no significant differences between patients with PCA and HS with respect to age
(73.2±7.2 and 68.8±9.8 years respectively) and gender distribution (M/F:2/3 and 3/2 respec-
tively). All patients showed similar symptoms at onset, including visual, reading and driving
difficulties, dyscalculia, spatial disorientation and recent memory disturbances. On neurologi-
cal examination, elements of Balint's and Gerstmann's syndromes were documented in all
patients. Neuropsychological testing revealed a remarkable impairment in global cognition in
all patients, as measured by MMSE (Tables 1 and 2). With respect to assessment of single
domains (Table 2), patients performed poorly in most areas of cognition, with their worst per-
formance in visuospatial abilities. With respect to episodic memory, on average, patients per-
formed under the cut-off of normality. However, this performance was higher than that
expected in patients with typical AD and a similar level of global cognitive impairment [28].
CSF analysis showed decreased beta amyloid levels in all patients and increase of Tau and Ptau
concentration in 4 out of 5 patients (Table 1).
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Voxel Based Morphometry
When comparing PCA patients against controls, the former group showed a widespread distri-
bution of regional grey matter loss affecting the posterior brain areas (predominantly on the
right hemisphere) (PFWEcorr<0.05), as shown in Fig 2. This pattern of grey matter atrophy
included the parastriate and peristriate occipital lobe cortices (BA18 and BA19 respectively)
and the posterior part of the temporal lobes (superior temporal gyrus BA22, BA41) and of pari-
etal lobes (angular gyrus BA39, precuneus and superior parietal lobule BA7). Additionally, a
region of significant grey matter loss was also identified in the right frontal lobe of PCA
patients (frontal eye field BA8, anterior prefrontal cortex BA10). No regions of reduced grey
matter volumes were found in healthy controls as compared to patients. No significant correla-
tion was observed between patients’ regional grey matter volumes and CSF tau levels.
1HMRS
The averages of the metabolite ratios obtained from all voxels positioned in the occipital lobe
(right and left) showed decreased neuronal integrity marker NAA/Cr (PCA 1.26 ± 0.19, HC
1.64 ± 0.29, t-test p 0.0028) and increased glial marker Ins/Cr (PCA 1.13 ± 0.23, HC
Fig 1. Volumes of interest (VOIs; size = 20x20x20mm) investigated by 1HMRS (top panel). Typical spectra obtained from VOIs positioned in the
occipital lobes of a control subject and a patient with PCA are also shown (bottom panel) See text for further details.
doi:10.1371/journal.pone.0140639.g001
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0.83 ± 0.14, t-test p 0.0021). Voxels from the posterior cingulate cortex revealed a decrease in
patient’s NAA/Cr (PCA 1.19 ± 0.08, HC 1.38 ± 0.07, t-test p 0.0046) (Fig 3). When comparing
right and left hemispheres in the patient group, there was no significant difference in any of the
considered VOIs (p values ranging from 0.25 to 0.98).
Discussion
Herein, we described a group of patients with PCA, characterized clinically and neuropsycho-
logically, who were investigated using quantitative MR techniques. This clinical condition has
become of increasing interest, since the clinical onset of a relevant proportion of patients with
Alzheimer’s disease is dominated by non-typical symptoms [29]. The clinical features of our
PCA patients are similar to those previously described by others [5,9,11,30,31]. Their profile
was characterized by visual, reading and driving difficulties, dyscalculia, spatial disorientation,
and elements of Balint's and Gerstmann's syndrome. Less severe memory impairments for
recent events were also present in our patient group. A diagnosis of amyloid-based dementia
was supported by CSF biomarkers, with the demonstration of low levels of beta-amyloid in all
cases, and increased levels of total Tau and Ptau the majority of them. This CSF profile has
been associated with the presence of Alzheimer's disease pathology (i.e., neurofibrillary tangles
and amyloid plaques,) with a predictive value of 90% [32], and PCA is currently regarded, in
most cases, as a focal variant of Alzheimer’s disease [29,31,33,34,35].
When using VBM for an unbiased assessment of grey matter volumes, our PCA patients
showed a posterior pattern of cortical atrophy, which fits well with their clinical and neuropsy-
chological characteristics. The anatomical distribution of GM loss in the patient group involved
the secondary visual cortex, the visual association cortices and the posterior part of the tempo-
ral and of parietal lobes. All these cortical regions are known to play a major role in visual per-
ception and interpretation of sensory information, and their selective damage has been
consistently reported in patients with PCA [9,36,37,38]. Our PCA patients showed also an
asymmetrical distribution of GM atrophy, which was predominant on the right hemisphere.
Fig 2. VBM analysis: PCA patients compared to healthy controls showed a widespread pattern of bilateral greymatter loss, predominantly
affecting the posterior areas of the brain. The opposite contrast (PCA patients more than controls) did not reveal any significant difference. Statistical
threshold: p<0.05 Family Wise Error (FWE) corrected at cluster level. See text for further details.
doi:10.1371/journal.pone.0140639.g002
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This finding is also consistent with previous reports, which have demonstrated right hemi-
sphere predominance in patients with PCA [8,10,12,13,39,40]. Additionally, our PCA group
revealed an area of focal GM loss in the right prefrontal cortex. This area coincides with the
frontal eye fields, which have been previously described as hypomethabolic and atrophic in
PCA patients [10,13]. This focal loss of GMmay also contribute in accounting for some pecu-
liar clinical features of PCA such as ocular apraxia, and is likely secondary to structural discon-
nection of fibers originating from the occipito–parietal cortices. Additionally, our specific
group of patients showed some minor deficits in memory retrieval and executive functions,
which might be, at least partially, explained by prefrontal damage. Regarding CSF tau levels,
which represent a marker of neurodegeneration, there were no significant correlations between
patients’ grey matter volumes and such levels. Nevertheless, four out of five patients had very
high tau levels (clearly out of reference range) with poor intersubject variability. The fact that
values were very similar across patients, together with the small sample size, may account for
the lack of correlation.
GM volumetrics is certainly quite a useful approach to associate clinical aspects of disease
with anatomical patterns of brain tissue damage. However, atrophy is only the final step of neu-
rodegeneration, and its assessment is poorly informative on the underlying pathophysiological
mechanisms. Conversely, 1HMRS provides metabolic information on the brain tissue in vivo,
and has already been used to investigate single regions of PCA brains [13]. Notably, this is the
Fig 3. Column graphs showingmean and standard deviations of 1H MRSmetabolite ratios (NAA/Cr, Cho/Cr and Ins/Cr) form the different VOIs in
patients with PCA (orange) and healthy controls (blue). In the case of bilateral VOIs (i.e., occipital lobe and centrum semiovale), left and right measures
were averaged. PCA patients compared to controls showed a significant decrease of NAA/Cr in the occipital lobes (panel A) and in the posterior cingulate
gyrus (panel B). Additionally, PCA patients showed a significant increase of Ins/Cr in the occipital lobes (panel A). No significant between group differences
were observed in the anterior cingulum (panel C) and in the centrum semiovale. Statistical threshold: p>0.012 after Bonferroni’s correction. See text for
further details.
doi:10.1371/journal.pone.0140639.g003
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first study that applied 1HMRS to multiple brain regions in the same cohort of PCA patients,
thus allowing, together with GM volumetrics, a better definition of the pathophysiological tra-
jectory of the disease. Indeed, within the limitation of a cross-sectional design, metabolic
abnormalities are supposed to precede the brain tissue loss, although this speculation needs to
be confirmed by longitudinal investigations. When focusing on the occipital lobes, 1H-MRS
revealed decreased levels of NAA/Cr and increased levels of Ins/Cr in PCA patients compared
to controls. NAA is a neuronal protein, whose decrease is widely regarded as a marker of neu-
ronal loss [27], especially in neurodegenerative conditions. Conversely, Ins is considered as a
marker of gliosis, which we found to be altered in the occipital lobes (the anatomical core of
PCA pathology), but not in other brain areas. Changes in both markers are likely to occur at
different disease stages and in different brain regions, and might represent sensitive biomarkers
of disease evolution. However, longitudinal studies are needed to clarify the usefulness of MRS
in providing early disease markers and information of potential prognostic value. Consistent
with a previous report [13], we observed here a reduction of NAA/Cr also in the posterior cin-
gulate cortex of our PCA patients. This is of particular interest for at least two reasons. The pos-
terior cingulate cortex is the most critical node of the so-called default mode network, which
goes disrupted across AD progression [41] but not in other forms of dementia, such as, for
instance, the frontotemporal dementia [42]. This supports the idea that PCA is in most cases a
focal variant of AD. Second, this selective damage might contribute in accounting for the mem-
ory deficits we observed in our PCA patients, which were present but less pronounced than
those expected in patients with typical AD [28].
The centrum semiovale and the anterior cingulate cortex of our PCA patients did not reveal
any significant abnormality when considering either structural or metabolic measures. These
negative findings are also of clinical interest, as they suggest a potential role of quantitative
MRI in supporting the differential diagnosis between PCA and other neurodegenerative forms
of cognitive decline. However, again, further studies on larger populations are needed to
address this point.
A major limitation of the present study (and previous research in the field of PCA) is the rel-
atively small number of participants. In an attempt to overcome small samples and other issues
of individual studies, Alves et al. in 2013 performed a meta-analytic review of neuropsychologi-
cal and brain morphometry PCA studies [14]. With respect to the common data between such
a meta-analysis and the current investigation, results are fully consistent. However, due to the
relatively low incidence of PCA, future multi-centric studies (possibly with a longitudinal
design) employing comparable protocols of data collection are needed. This is relevant not
only for increasing our knowledge on PCA pathophysiology, but also for planning future clini-
cal trials. With respect to proton MRS, according to our data, it may be useful for a better defi-
nition of the disease, and could also be considered in view of future treatments for a more
accurate patient selection and monitoring.
Due to the single-voxel MRS approach we employed here, another limitation of the current
study is the lack of metabolic information from the whole brain. In particular, it has been
recently shown that the parietal lobe is an early target of PCA pathology [43,44]. Again, future
MRS studies are needed to further explore this aspect.
In conclusion, within the limitation of a small sample size, this study indicates the potential
usefulness of a multi-parametric MRI approach, in combination with CSF biomarkers, for the
differential diagnosis and staging of patients with PCA. This is relevant not only for speculative
reasons but also for setting up reliable tools of disease monitoring to be applied to studies of
natural history and clinical trials.
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